View of Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study

Return to Article Details Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study Download Download PDF